AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11254512
Drug: Postmenopausal women
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postmenopausal women with hormone replacement therapy (HRT)
Trial: 7596206
Drug: Other internal
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other internal medicine services
Trial: 2551204
Drug: BID regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID regimen (twice a day)
Trial: 30418579
Drug: n‐3 LCPUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 LCPUFA (2.4 g daily)
Trial: 26100924
Drug: 90μg HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90μg HPV vaccine
Trial: 26100924
Drug: 60μg HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60μg HPV vaccine
Trial: 26100924
Drug: 30μg HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30μg HPV vaccine
Trial: 26100924
Drug: Control hepatitis
RxNorm normalized name: hepatitis A virus strain CR 326F antigen, inactivated Injection [Vaqta]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control hepatitis B vaccine
Trial: 20337634
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg b.i.d. on Day 5 of a 7-day regimen
Trial: 20337634
Drug: Laropiprant 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laropiprant 40 mg alone
Trial: 19298202
Drug: L-diet
RxNorm normalized name: ethyl-diethylphosphoric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-diet
Trial: 11229106
Drug: prazosin GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prazosin GITS 2.5 mg OD
Trial: 11229106
Drug: atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol 50 mg OD
Trial: 11229106
Drug: nifedipine SR
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nifedipine SR 20 mg BD
Trial: 11229106
Drug: enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 5 mg OD
Trial: 3497450
Drug: Norfloxacin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (1200 mg)
Trial: 3497450
Drug: Cotrimoxazole (480/2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (480/2400 mg)
Trial: 29104121
Drug: Vesatolimod (1-,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vesatolimod (1-, 2-, or 4-mg doses) administered once weekly for 4, 8, or 12 weeks
Trial: 29104121
Drug: Placebo (PBO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PBO) administered once weekly for 4, 8, or 12 weeks
Trial: 16998266
Drug: Candesartan (angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (angiotensin II type 1 receptor blocker)
Trial: 16998266
Drug: Amlodipine (dihydropiridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (dihydropiridine calcium antagonist)
Trial: 11049913
Drug: Tramadol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 2.5 mg/kg (Group 1)
Trial: 11049913
Drug: Tramadol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 1.25 mg/kg + lysine acetyl salicylate 12.5 mg/kg (Group 2)
Trial: 9284852
Drug: Compound 48/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound 48/80 (reversed microdialysis)
Trial: 1329673
Drug: Thymopentin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin (50 mg injections three times a week for six weeks)
Trial: 7818590
Drug: Thymopentin treatment
RxNorm normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin treatment
Trial: 3919557
Drug: Bepridil once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil once daily
Trial: 31605792
Drug: Comparator (EGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator (EGFR tyrosine kinase inhibitors)
Trial: 30442122
Drug: Current practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current practice of BP lowering therapy
Trial: 30442122
Drug: Intermediate risk
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate risk threshold for BP lowering therapy
Trial: 30442122
Drug: High risk
RxNorm normalized name: Hep B, adolescent/high risk infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High risk threshold for BP lowering therapy
Trial: 26369526
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg basiliximab with cyclosporine (control)
Trial: 26369526
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg basiliximab with cyclosporine
Trial: 26369526
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg basiliximab with everolimus (CNI-free)
Trial: 19183087
Drug: Oral amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amitriptyline (10-20 mg/day)
Trial: 19183087
Drug: Topical triamcinolone
RxNorm normalized name: triamcinolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical triamcinolone plus oral amitriptyline (10-20 mg/day)
Trial: 15823767
Drug: Mix 75/25
RxNorm normalized name: HumaLOG Mix 75/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mix 75/25 plus metformin
Trial: 10852983
Drug: Prednisone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (60 mg/day) alone (group A)
Trial: 10852983
Drug: Prednisone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (60 mg/day) combined with cyclical etidronate (group B)
Trial: 9612103
Drug: Cefotaxime and
RxNorm normalized name: cefotaxime and beta-lactamase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime and metronidazole combination
Trial: 3094172
Drug: Thiamphenicol (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamphenicol (single oral dose)
Trial: 3094172
Drug: Lymecycline (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymecycline (two 1.5-g oral doses taken 12 hr apart)
Trial: 30365202
Drug: Cebranopadol (200–1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cebranopadol (200–1,000 μg)
Trial: 30365202
Drug: Morphine prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine prolonged release (PR) (≤120 mg daily)
Trial: 30365202
Drug: Cebranopadol and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cebranopadol and Morphine PR
Trial: 28459958
Drug: TRV027 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV027 1 mg/h
Trial: 28986703
Drug: TRV027 (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV027 (lower doses)
Trial: 24214165
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy intervention (30 sessions)
Trial: 17492582
Drug: SNRIs (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNRIs (selective noradrenaline reuptake inhibitors)
Trial: 17492582
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of behavior therapy and SSRIs (selective serotonin reuptake inhibitors)
Trial: 17492582
Drug: Adding an
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adding an SSRI, an SNRI, or an atypical antipsychotic to an SSRI
Trial: 12633543
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor captopril
Trial: 9181900
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg p.o. daily for six months
Trial: 9181900
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg p.o. daily for fourteen days, then reduced to 10 mg for a total treatment period of six months
Trial: 8398713
Drug: Verapamil (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (120 mg qid for 5 days with each course of chemotherapy)
Trial: 8398713
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (chemotherapy without verapamil)
Trial: 3299394
Drug: ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ferrous sulphate (100 mg/day)
Trial: 3299394
Drug: ferritin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ferritin (80 mg/day as Fe3+)
Trial: 3299394
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of ferritin (80 mg Fe3+/day), folinic acid and vitamin B12 coenzyme
Trial: 24851692
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg rt-PA with catheter-directed thrombolysis
Trial: 24851692
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rt-PA with catheter-directed thrombolysis
Trial: 22480663
Drug: D-cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine (DCS) 50 mg administered 1 hour before each exposure session
Trial: 22480663
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 1 hour before each exposure session
Trial: 10510162
Drug: 8 micromol
RxNorm normalized name: BENZALKONIUM CHLORIDE 0.3068 g in 236 mL TOPICAL SOAP [MicroGold Anti-Bacterial Waterless Hand (4 oz.)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 micromol min‐1 N‐monomethyl L‐arginine (L‐NMMA)
Trial: 8787171
Drug: Cladribine (new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladribine (new immunosuppressive drug)
Trial: 6404577
Drug: Tiapamil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapamil (200 mg t.i.d.)
Trial: 26524699
Drug: 8-week CCR
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8-week CCR based on Nordic walking training (five times weekly) at 40-70% of maximal heart rate
Trial: 22966414
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (Kaneka QH ubiquinol; 300 mg per day)
Trial: 17218573
Drug: Montelukast (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (4 mg/d)
Trial: 11156217
Drug: GMK vaccine
RxNorm normalized name: GMK vaccine
DrugBank: GMK (DB06661)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMK vaccine (30 microg of G(M2)) and GDK (various doses)
Trial: 11156217
Drug: GDK (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDK (30 or 70 microg of G(D2))
Trial: 11156217
Drug: GDK (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDK (various doses)
Trial: 11156217
Drug: GDK (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDK (highest dose level)
Trial: 8891621
Drug: Gentamicin 80
RxNorm normalized name: gentamicin 80 mg/50 mL-0.9% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 80 mg
Trial: 6625729
Drug: 1 X
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 X 40 mg kg‐1 (Group A)
Trial: 6625729
Drug: 2 X
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 X 20 mg kg‐1 (Group B)
Trial: 6625729
Drug: 1 X
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 X 40 mg kg‐1 (Camps)
Trial: 31301057
Drug: Traditional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional physical therapy intervention strategies (Group A)
Trial: 28708216
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic antibiotics (Group B)
Trial: 7995325
Drug: Progesterone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (300 mg)
Trial: 30778667
Drug: 6% L-ascorbate-2-phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% L-ascorbate-2-phosphate trisodium salt (APS) in test lotion (TL)
Trial: 30778667
Drug: Placebo lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lotion (PL)
Trial: 29395188
Drug: Naltrexone (50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50mg daily for 3 weeks)
Trial: 29395188
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 3 weeks)
Trial: 27872863
Drug: sustained-release methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained-release methylphenidate
Trial: 22531559
Drug: Pressure Support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure Support Ventilation (PSV) with Sighs (30 cm H2O peak airway pressure, administered once per minute)
Trial: 18829790
Drug: Bifidobacterium bifidum
RxNorm normalized name: Bifidobacterium Bifidum
DrugBank: Bifidobacterium bifidum (DB16538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium bifidum and Lactobacillus acidophilus added to breast milk or mixed feeding, twice daily for 6 weeks
Trial: 12425849
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 50% nitrous oxide and oxygen
Trial: 12425849
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of air and oxygen (Control)
Trial: 31227872
Drug: G allele
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G allele at rs2893881
Trial: 29308593
Drug: ADF IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADF IR formulation of an opioid
Trial: 29308593
Drug: Marketed IR
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed IR formulation
Trial: 24777621
Drug: Probiotic food
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic food supplement (Lactobacillus rhamnosus R0011 1.9×10^9 cfu and L. acidophilus R0052 0.1×10^9 cfu/d for 7 days)
Trial: 24777621
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (oral rehydration solution and zinc)
Trial: 24777621
Drug: Probiotic food
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic food supplement
Trial: 23586657
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg administered three times per day for 48 hours
Trial: 23586657
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered three times per day for 48 hours
Trial: 21473840
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT) before laser preparation
Trial: 21473840
Drug: Non-LLT (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-LLT (without low level laser therapy) before laser preparation
Trial: 19770393
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) 10 microg/kg, n=26
Trial: 17324738
Drug: Lisinopril 5
RxNorm normalized name: lisinopril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 5 mg (n = 18)
Trial: 17324738
Drug: Lisinopril (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (after 14 days)
Trial: 15155205
Drug: Atazanavir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir (300 mg) and Ritonavir (100 mg) QD + Tenofovir DF QD (from day 15)
Trial: 15155205
Drug: Atazanavir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir (300 mg) and Ritonavir (100 mg) QD
Trial: 7991905
Drug: Propofol (1.5‐2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5‐2.5 mg/kg for induction; 6‐12 mg/kg continuous infusion for maintenance)
Trial: 7991905
Drug: Neuroleptanalgesia (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptanalgesia (sodium thiopental 4‐5 mg/kg for induction; droperidol 0.15 microgram/kg/h and 50% N2O/O2 for maintenance)
Trial: 2903110
Drug: Pentasa (5-aminosalicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentasa (5-aminosalicylic acid) 1500 mg t.i.d. (three times a day)
Trial: 2903110
Drug: Salazopyrin (sulfasalazine)
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salazopyrin (sulfasalazine) 3 g t.i.d.
Trial: 28745686
Drug: LPD (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPD (0.6 g of protein per kg of body weight/day) with keto/amino acid ketosteril (1 tablet per 5 kg of body weight/day)
Trial: 28745686
Drug: LPD (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPD (0.6 g of protein per kg of body weight/day) with keto/amino acid ketoaminol (1 tablet per 5 kg of body weight/day)
Trial: 24120216
Drug: Efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV) 600 mg once-daily
Trial: 24120216
Drug: Nevirapine (NVP)
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine (NVP) 400 mg once-daily
Trial: 17154666
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with beta-lactam plus macrolide
Trial: 17154666
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with respiratory fluoroquinolone
Trial: 17154666
Drug: Beta-lactam alone
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-lactam alone at adequate dosage
Trial: 11012656
Drug: Saline (dummy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (dummy injection)
Trial: 3917884
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate infusion
Trial: 3917884
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution (saline) infusion
Trial: 28865067
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment in sleep unit (SU) setting
Trial: 28865067
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment in primary care (PC) setting
Trial: 20102888
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy (low-dose bisoprolol regimen started ≥30 days before surgery)
Trial: 20102888
Drug: No beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta-blocker therapy (control group)
Trial: 17469694
Drug: Lithium plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium plus fluoxetine
Trial: 16036038
Drug: Fibrinolysis treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolysis treatment
Trial: 12073958
Drug: Self-monitoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring of blood glucose (SMBG), measured 4 times daily using a reflectance meter with memory
Trial: 9796636
Drug: PXM 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PXM 10 mg every other day (q.o.d.)
Trial: 9796636
Drug: DFMO 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFMO 0.5 g/m2
Trial: 9796636
Drug: PXM 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PXM 10 mg q.o.d.
Trial: 9796636
Drug: DFMO/PXM combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFMO/PXM combination
Trial: 24477618
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of α‐lipoic acid (ALA) 600 mg and superoxide dismutase (SOD) 140 IU daily with physiotherapy
Trial: 15992517
Drug: Esterified plant
RxNorm normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esterified plant stanols (2 to 3 g/day) incorporated in margarines or spreads
Trial: 10102975
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg ranitidine
Trial: 7568481
Drug: Midazolam 0.1
RxNorm normalized name: midazolam 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.1 mg/kg plus ketamine 0.4 to 0.5 mg/kg
Trial: 2174783
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) s.c. every 12 h, initial dose about 100 U/kg bodyweight
Trial: 31626649
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (0.25 mg)
Trial: 15709843
Drug: Teacher-administered cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teacher-administered cognitive-behavioral intervention